Magenta Therapeutics

109 articles with Magenta Therapeutics

• Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Magenta Therapeutics to Present at the 39 th Annual J.P. Morgan Healthcare Conference

• Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditioning Program MGTA-117 at ASH Annual Meeting

  12/7/2020

  – Enrollment commenced in the MGTA-145 Phase 2 clinical trial of autologous transplant of multiple myeloma patients at Stanford University – – Oral presentation of Phase 1 clinical data presented at the 62 nd American Society of Hematology (ASH) Annual Meeting confirming MGTA-145 achieved proof-of concept: all safety and efficacy endpoints met and mobilized cells demonstrated functional superiority over other mobilization approaches in preclinical study

• Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

  12/4/2020

  Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD).

• 

  BioSpace Movers & Shakers, November 13

  11/13/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer

  11/9/2020

  Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer. “We welcome Steve to Magenta as a seasoned biotech executive with a strong leadership background,” said Jason Gardner, D.Phil., Chief Executive Officer and Pre

• Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results

  11/5/2020

  – Magenta advanced its MGTA-145 mobilization program, with two Phase 2 trials to be initiated by end of 2020; the Company’s MGTA-117 conditioning program is on track to file an IND and generate clinical data in 2021; – Magenta announced appointment of Lisa M. Olson, Ph.D., as Head of Research and Chief Scientific Officer – – Magenta named co-recipient of a U19 grant from the National Institutes of Health as part of an interdisciplinary effort

• Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting

  11/4/2020

  – Magenta will present a total of five abstracts, including an oral presentation highlighting clinical and preclinical data across its mobilization and conditioning pipeline – – Oral presentation of completed Phase I clinical trial confirms that MGTA-145, a novel biologic, robustly mobilized large numbers of functional hematopoietic stem cells (HSCs) for autologous and allogeneic stem cell transplant –

• Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September

  9/11/2020

  Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences: Cantor Virtual Global Healthcare Conference, presentation at 8:00 a.m. ET on Wednesday, September 16 Oppenheimer Virtual Fall Healthcare Li

• Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operating and Financial Officer

  9/2/2020

  Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality. The Company also announced that Jason Ryan will transition fro

• Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV

  9/2/2020

  – NIH grant funds an interdisciplinary effort among researchers from University of Southern California; University of Washington and Fred Hutchinson Cancer Research Center; Harvard University and Massachusetts General Hospital; the Ragon Institute; and Magenta Therapeutics – – Magenta will utilize its tool CD45 and CD117 antibody-drug conjugate (ADC) conditioning agents, as well as its stem cell biology platform to identify the optimal strategy for cur

• Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting

  8/31/2020

  Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held August 29 to September 1, 2020.

• Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results

  8/6/2020

  – Collaborations announced with AVROBIO and Beam Therapeutics to evaluate potential usage of MGTA-117 in conditioning patients in gene therapy and gene editing settings, respectively — – MGTA-145 to move into Phase 2 trials in autologous and allogeneic transplant in 2020, including allogeneic study in newly announced collaboration with National Marrow Donor Program® (NMDP)/Be The Match® - – Ended quarter with $176.5 million in cash, cash equivale

• Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  6/30/2020

  Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to

• Magenta Therapeutics Announces Pricing of Public Offering - June 25, 2020

  6/25/2020

  Magenta Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share.

• Magenta Therapeutics Launches Proposed Public Offering - June 24, 2020

  6/24/2020

  Magenta Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock.

• Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

  6/15/2020

  MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia

• 

  Magenta Enters Collaboration Agreement with Beam to Further Explore MGTA-117

  6/15/2020

  The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with sickle cell disease and beta-thalassemia.

• Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones

  6/11/2020

  Magenta Therapeutics Provides Portfolio Update : Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones — MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic study in newly announced collaboration with National Marrow Donor Program® (NMDP)/Be The Match® — — MGTA-117 antibody-drug conjugate (ADC)-based conditioning progr

• Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Subsequent Patient Transplant

  6/11/2020

  Collaboration focuses on clinical development of MGTA-145 for stem cell mobilization in allogeneic transplant in patients with blood cancers

• Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences

  6/8/2020

  Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41st annual Goldman Sachs Healthcare Conference on June 11th, 2020.